Athenex Inc (NASDAQ:ATNX) shares saw an uptick in trading volume on Friday . 4,670,100 shares traded hands during trading, an increase of 1,213% from the previous session’s volume of 355,816 shares.The stock last traded at $19.05 and had previously closed at $18.62.
Several research firms recently commented on ATNX. Zacks Investment Research upgraded shares of Athenex from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Friday, June 8th. BidaskClub upgraded shares of Athenex from a “hold” rating to a “buy” rating in a research note on Wednesday. ValuEngine upgraded shares of Athenex from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Needham & Company LLC began coverage on shares of Athenex in a research note on Tuesday, March 6th. They set a “buy” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $26.71.
Get Athenex alerts:The firm has a market cap of $1.17 billion and a PE ratio of -8.21.
Athenex (NASDAQ:ATNX) last announced its quarterly earnings results on Monday, May 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.05). The business had revenue of $37.84 million during the quarter. Athenex had a negative net margin of 136.72% and a negative return on equity of 75.45%. equities research analysts forecast that Athenex Inc will post -1.36 EPS for the current year.
In other Athenex news, EVP Rudolf Kwan purchased 2,000 shares of the stock in a transaction on Monday, March 26th. The shares were purchased at an average price of $14.65 per share, with a total value of $29,300.00. Following the acquisition, the executive vice president now directly owns 82,224 shares of the company’s stock, valued at approximately $1,204,581.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Jeffrey Yordon purchased 5,000 shares of the stock in a transaction on Monday, March 26th. The stock was acquired at an average cost of $14.69 per share, for a total transaction of $73,450.00. Following the acquisition, the insider now directly owns 188,709 shares in the company, valued at $2,772,135.21. The disclosure for this purchase can be found here. In the last three months, insiders acquired 29,500 shares of company stock worth $433,850 and sold 301,392 shares worth $5,041,671. Insiders own 29.50% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in shares of Athenex by 3,671.6% in the 1st quarter. Royal Bank of Canada now owns 60,874 shares of the company’s stock worth $1,035,000 after purchasing an additional 59,260 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Athenex by 108.8% in the 1st quarter. Millennium Management LLC now owns 133,663 shares of the company’s stock worth $2,274,000 after purchasing an additional 69,661 shares during the last quarter. LPL Financial LLC bought a new stake in shares of Athenex in the 1st quarter worth about $315,000. Ladenburg Thalmann Financial Services Inc. bought a new stake in shares of Athenex in the 1st quarter worth about $1,179,000. Finally, Jane Street Group LLC bought a new stake in shares of Athenex in the 1st quarter worth about $208,000. 16.63% of the stock is currently owned by institutional investors and hedge funds.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
No comments:
Post a Comment